Talis Biomedical Corporation announced new data supporting the development of its planned CT/NG/TV and vaginal infection panels. Results from these studies, presented in poster sessions at the 2023 IDSOG Annual Meeting in Denver, Colorado, support Talis Biomedical's mission to advance health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care. Preliminary clinical performance of the Talis One development-stage CT/NG/TV test was assessed using residual clinical samples initially tested by widely used, on-market molecular tests that require up to 90 minutes to generate a result.

In neat male urine, positive% agreement (PPA) was 100% for CT, NG and TV. Negative percent agreement (NPA) was 100% forCT and NG, and 98% for TV. In female vaginal swabs where only positive samples were tested, PPA was 100% for CT and NG, and 90% for TV.

In female female vaginal swabs where onlypositive samples were tested, PPA were 100% for CT and NG. In female vaginal swabs which only positive samples were tested, pPA was 100% for CT,NG, and 90% for TV; On-cartridge bead beating differentiates Talis One lysis for future development of vaginal panel;Talis Biomedical conducted a series of analytical studies to test different mechanical lysis conditions on the Talis One system to determine the feasibility of nucleic acid recovery from difficult-to-lyse fungal pathogens. Company scientists performed initial experiments to determine lysis efficiency with and without beads added to the Talis One's on-cartridge mechanical (stir bar containing) lysis chamber.

The lysis conditions were evaluated and selected using intact Candida albican as a model pathogen. The Talis One system is a compact, sample-to-answer molecular testing platform designed to enable rapid, highly accurate point-of care infectious disease testing in non-laboratory settings. The Talis One test cartridge is a fully self-contained, closed device that includes all the necessary reagents to perform a Talis One test.

When loaded into the Talis One instrument, each cartridge fully automates sample lysis, nucleic acid extraction and purification, isothermal amplification, and target detection. The Talis One test system is not authorized, cleared, or approved by the FDA and is not available for sale.